Royal Bank of Canada Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Royal Bank of Canada for the month of August 2011, with a filing date of August 1, 2011. The report serves to incorporate by reference exhibits related to the issuance of Senior Global Medium-Term Notes, Series E, pursuant to the Bank's shelf registration statement on Form F-3 (File No. 333-171806).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the issuance of specific structured securities rather than reporting general financial performance.
Material Changes and Issuance Details
The Bank issued four tranches of structured notes with a combined principal amount of $5,708,000. The specific issuances are as follows:
- Enhanced Growth Securities: Linked to the iShares Russell 2000 Index Fund, due February 3, 2014. Principal: $1,270,000. Settlement: August 1, 2011.
- Buffered Bullish Enhanced Return Notes: Linked to the S&P 500 Index, due August 31, 2012. Principal: $1,879,000. Settlement: August 2, 2011.
- Reverse Convertible Notes: Linked to the Common Stock of Human Genome Sciences, Inc. Principal: $605,000. Settlement: August 2, 2011.
- Buffered Bullish Enhanced Return Notes: Linked to the iShares MSCI EAFE Index Fund, due August 31, 2012. Principal: $1,954,000. Settlement: August 2, 2011.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, or outlook. The primary risks and contingencies are inherent to the structured nature of the notes, which include capped upside, fixed percentage buffered downside, and reverse convertible features linked to specific equity indices or individual stocks. Legal opinions regarding the validity of the notes under Canadian, Ontario, Quebec, and New York law were filed as exhibits.
Investor Verification Checklist
- Verify the specific payoff structures and downside protection levels for the "Buffered Bullish" and "Enhanced Growth" notes.
- Confirm the credit risk exposure associated with the Reverse Convertible Notes linked to Human Genome Sciences, Inc.
- Review the full text of the Pricing Supplements dated July 27 and July 28, 2011, for detailed terms not included in this summary.
- Check the status of the underlying indices (Russell 2000, S&P 500, MSCI EAFE) and the specific stock (Human Genome Sciences) at the time of settlement.